Genflow Biosciences (LSE:GENF) EBITDA Margin %: 0.00% (As of Dec. 2025)


What is Genflow Biosciences EBITDA Margin %?

Genflow Biosciences LSE:GENF EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Genflow Biosciences ranks worse than 105820% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genflow Biosciences's EBITDA for the six months ended in Dec. 2025 was £-0.68 Mil. Genflow Biosciences's Revenue for the six months ended in Dec. 2025 was £0.00 Mil. Therefore, Genflow Biosciences's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.

Genflow Biosciences  (LSE:GENF) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Genflow Biosciences EBITDA Margin % Related Terms

Genflow Biosciences EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences EBITDA Margin % Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
0.00 0.00 0.00 0.00 0.00

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LSE:GENF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Genflow Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genflow Biosciences EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genflow Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Genflow Biosciences's EBITDA Margin % falls into.


Genflow Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Genflow Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-1.416/0
= %

Genflow Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.679/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Genflow Biosciences (LSE:GENF) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genflow Biosciences and its competitors. According to the industry distribution chart, Genflow Biosciences ranks #999999 out of 945 companies in the Biotechnology industry.
Is Genflow Biosciences' EBITDA Margin % too high?
Genflow Biosciences' current EBITDA Margin % is 0.00%. Based on the distribution chart, Genflow Biosciences ranks #999999 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Genflow Biosciences' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genflow Biosciences ranks #999999 out of 945 companies for EBITDA Margin %. This places Genflow Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (LSE:GENF) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genflow Biosciences (LSE:GENF), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENFF:USAWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.